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Conclusion: In conclusion, we improved and validated a 
clinical model with inclusion of hypoxia and tumor-load 
related blood-biomarkers. New immunological markers were 
associated with overall survival. Currently we are aiming to 
extend these models to include imaging information 
(Radiomics). 
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Purpose or Objective: Intensity-modulated radiation therapy 
(IMRT) and volumetric-modulated arc therapy (VMAT) are 
widely used in the treatment of advanced stage non-small 
cell lung cancer (NSCLC). These techniques deliver conformal 
dose distributions at the cost of increased target dose 
heterogeneity (particularly IMRT) and larger volumes of 
surrounding healthy tissues receiving low doses (particularly 
VMAT). We evaluated whether these dosimetric differences 
between IMRT and VMAT are of influence on treatment 
toxicity and outcome. 
 
Material and Methods: We retrospectively assessed a cohort 
of 189 consecutive patients with stage III NSCLC having 
undergone radical (chemo-)radiotherapy using IMRT (until 
2011) or VMAT (starting in 2011 ). Most patients (n=182) 
received 66 Gy in 33 (once-daily) fractions to the primary 
tumour and involved hilar/mediastinal lymph nodes based on 
FDG-PET/CT. Concurrent chemoradiation (CCR; n=122) 
consisted of 2 courses of etoposide cisplatinum, whereas 
sequential treatment (n=56) consisted of 3 courses of 
gemcitabine cisplatinum. Acute and late toxicity were 
assessed using the RTOG radiation morbidity scoring criteria 
for esophageal and pulmonary toxicity. Follow-up visits were 
planned every 3 months (first 2 years), biannually thereafter. 
Median overall survival (OS) was calculated using Kaplan-
Meyer survival analysis. Differences between the groups 
receiving IMRT and VMAT were statistically tested using the 
Mann-Whitney-U or Chi-square test, where appropriate. 
 
Results: Gender, age, performance score, clinical (tumour 
and nodal) stage and radiation dose did not significantly 
differ between the IMRT (n=93) and VMAT (n=96) groups. 
Patients undergoing IMRT, however, received less concurrent 
chemotherapy compared to patients treated with VMAT (n=51 
vs n=71; p= 0.007). Incidences of grade ≥2 and ≥3 acute 
esophageal toxicity (AET) were significantly lower for IMRT 
compared to VMAT (28 vs 57 patients, p<0.001; and 6 vs 17 
patients, p=0.025, respectively). Maximum grade acute and 
late pulmonary toxicity did not differ between groups (p=0.57 
and p=0.14, respectively). Grade ≥3 late esophageal toxicity 
was scored in 1 and 3 patients after IMRT and VMAT, 
respectively. Median follow-up for the patients alive was 32 
months (range 2.4-82.1 months). Median OS was 23.9 months 
(95% CI 19.6-28.1), without a significant difference between 
the groups (23.9 and 24.9 months for IMRT and VMAT, 
respectively; p=0.70). 
 
Conclusion: Patients treated with VMAT showed significantly 
higher incidence of Grade ≥2 and ≥3 AET, which may be due 
to a higher percentage of patients receiving CCR in the 
VMAT-group. Median OS did not differ between groups. 
Currently the target volumes and dosimetric data are 
evaluated for differences between the groups, for we 
hypothesized that VMAT enables treatment of larger tumour 
volumes, leading to increased AET. 
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Purpose or Objective: The purpose of the present study was 
to investigate the extent and appearance of early radiologic 
injury in the lung after radiotherapy (RT) for non-small cell 
lung cancer (NSCLC). Furthermore, the ability of planned 
mean lung dose to predict the risk of a radiologic response 
was explored. 
 
Material and Methods: Eligible follow-up computed 
tomography (CT) scans acquired within 6 months after 
commencement of radiotherapy were retrospectively 
evaluated for radiologic injuries in a cohort of 213 NSCLC 
patients treated to 60 or 66 Gy in 2 Gy fractions at a single 
institution from 2007 to 2013. Radiologic injuries were 
divided in two categories based on CT appearance. Category 
1 represented ground-glass opacity (GGO) and interstitial 
changes. Both are characterized by moderately increased 
densities in the lung parenchyma, but where GGO appears 
diffuse, amorphous, and with poorly defined vessel 
structures, interstitial changes are identified by more 
pronounced vessels and borders. Category 2 indicated patchy 
or confluent consolidation in the lung. The volume fraction of 
injured lung corresponding to either category was estimated 
in each scan. To investigate the relationship between the 
volume fraction of injured lung and mean lung dose, a 
logistic regression analysis was performed. Four different cut-
points were chosen to define radiologic injury response. 
These were volume fractions of injured lung larger than 5%, 
10%, 15%, or 20%. Both individual and combined categories 
were investigated. 
 
Results: Radiologic injuries of category 1 and 2 were found in 
follow-up scans for 81% and 42% of the patients, respectively. 
The mean volume fraction of injured lung was 6.5% (range 0-
95%) and 1.7% (range 0-22%) for category 1 and 2, 
respectively, and 8.2% (range 0-95%) when the categories 
were combined. The logistic normal tissue complication 
probability (NTCP) models are shown in the figure for the 
combined categories of lung appearance. The risk of 
radiologic response was found to be significantly associated 
with mean lung dose. The mean lung dose resulting in 50% 
risk of radiologic response (D50) increased from 17 to 29 Gy 
as the cut-point used for dichotomization increased from 5 to 
20% of volume fraction of affected lung (see table). A logistic 
relationship between radiologic response and mean lung dose 
was also found for the individual categories of lung 
S318                                                                                                                                                    ESTRO 35 2016 
______________________________________________________________________________________________________ 
appearance (see table). In these cases, increased D50 values 
were found since the frequency of response was reduced. 
 
 
 
 
 
Conclusion: Radiologic injuries were frequently found in 
follow-up CT scans after RT for NSCLC patients. Logistic 
relationships between the risk of a radiologic response and 
increasing mean lung dose were observed both when 
categorizing the lung injuries in terms of appearance and 
when combining the categories. 
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Purpose or Objective: Although many studies have 
confirmed the synergic effects of combining chemotherapy 
and radiotherapy (RT), clinical data evaluating safety and 
efficacy of erlotinib in combination with RT in locally 
advanced non-small-cell lung carcinoma (NSCLC) are limited. 
This is the first study to determine the feasibility, 
tolerability, and efficacy of the concurrent addition of 
erlotinib to the standard conformal thoracic RT in patients 
with unresectable or locally advanced NSCLC who are not 
candidates for receiving standard CT by any cause. 
 
Material and Methods: 90 patients (p) with irresectable 
NSCLC (I-IIIB stage), ECOG < 2 and measurable disease for 
criteria RECIST were randomized. P assigned to the arm A 
received RT 3D (66 Gy/33 fractions) and P in the arm B 
received the same RT with erlotinib 150 mg/d p.o. 
concurrent up to a maximum of 6 months. The principal aim 
was the G 3-4 toxicity the secondary aims: OS, PFS, cause-
specific survival (CSS), and objective response rate (ORR). 
 
Results: 90 p were included (30 in arm A, 60 in B), 89 were 
valid for safety analysis and 81 of efficacy. Responses: CR 
A/B (%): 21,4/ 41,5 (p <0,05). Median of follow-up 17,1 m. 
OS: 15,3/ 12,9 m (p: NS). CSS: 17,7/ 21,4 m (p: NS). G 3-4 
toxicities: A/B (%): pneumonitis: 10,6/3,3; radiodermitis: 
3/3,3); esofagitis: 0/0; pulmonary fibrosis: 0/3,3; 
cardiopathy: 3,4/1,6; rash: 0/13,3; diarrhea: 3,4/6,7; 
fatigue: 0/8,3. Erlotinib did not increase the toxicity 
produced by the RT. 
 
Conclusion: The combination of erlotinib with RT produces a 
scarce clinical benefit in this group of patients, limited to 
complete responses and longer CSS rate compared with RT 
alone. Increased toxicity events were associated with 
combined therapy, mainly cutaneous toxicity. Further studies 
in molecularly unselected lung cancer patients treated with 
EGFR TKIs and radiotherapy are not indicated. Use of 
predictive biomarkers to identify patients most likely to 
benefit are mandatory 
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Purpose or Objective: To evaluate the sites of relapse and 
prognostic factors of outcome in a retrospective series of 
patients with epithelial thymic tumors (ETT) treated 
consecutively with surgery and post operative RT. 
 
Material and Methods: Data from 134 ETT patients who were 
operated according to guidelines in different centres and 
received RT in Gustave Roussy from 1990 to 2011 was 
retrospectively analysed. Before 1998, patients had 
radiotherapy to the thymic region as well as elective nodal 
radiotherapy (ENRT) to the mediastinum and both supra-
clavicular regions. From 1999 on, patients had conformal RT 
limited to the thymic tumour bed. A 3D-conformal 
radiotherapy (CRT) with CT-based treatment planning was 
used from 1995, and Intensity Modulated Radiotherapy has 
been gradually implemented since 2010 
 
Results: Median follow-up was 8.8 years. Quality of resection 
was R0 in 75%, R1 in 22%, and R2 in 3% of patients. 16% had 
neoadjuvant chemotherapy. Classification according to 
Masaoka-Koga was: stage I/IIA in 17%, IIB in 22%, III in 28%, 
and IV in 33%. 28 patients (21%) had thymic carcinoma 
according to WHO classification. The mean (median? 
delivered dose of RT was 54 Gy (42-66) and 53% patients an 
ENRT at a dose of 45-50 Gy median dose different between 
ENI and CRT. Late toxicities were observed in 16% of patients 
(11 pneumonitis, 9 pericarditis and 6 coronaropathy) but no 
related toxic-death was reported. Considering patterns of 
relapse, there were 26 local relapses which could be 
considered in-field (46% pleura, 27% mediastinum, and 27% to 
both locations) and 42 regional relapses (88% pleura, 5% 
mediastinum, and 7% lung) resulting in a locoregional control 
(LRC) rate of 67%49% at 5/10 years. Distant control rate was 
91% at 10 years. ENI (HR: 2.3) and Masaoka-Koga 
classification > stage IIB (HR: 3.2) were associated with a 
decreased LRC in the multivariate analysis (MVA). Gender, 
age, WHO classification, PS, score, R0 status, CRT dose, and 
boost CRT Were not correlated with LRR in the MVA. The 
cause specific and overall survivals (OS) at 5 and 10 years 
were 72% and 63%, respectively (add 5 year results). PS>0 
(HR: 2.6), and Masaoka-Koga stage IV (HR: 2.1) correlated 
with a lower OS in the MVA. 
 
Conclusion: Masaoka-Koga was the main prognostic factor of 
OS and LRC in this analysis. Indications of RT should be 
